TrialInternational journal of hematology2017

Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations.

Keiji Nogami et al.PubMed ↗Publisher ↗

No numbers read from the abstract.